Related references
Note: Only part of the references are listed.Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology
Soo-Ryum Yang et al.
CANCER CYTOPATHOLOGY (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Gerald S. Falchook et al.
CLINICAL CANCER RESEARCH (2020)
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Adam J Schoenfeld et al.
CLINICAL CANCER RESEARCH (2020)
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer
M. A. Pruis et al.
LUNG CANCER (2020)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon et al.
NATURE MEDICINE (2020)
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes
Tianshi Lu et al.
SCIENCE IMMUNOLOGY (2020)
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients
J. H. Shim et al.
ANNALS OF ONCOLOGY (2020)
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Jacqueline H. Starrett et al.
CANCER RESEARCH (2020)
MSK-ACCESS for noninvasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA.
Emily S. Lebow et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evolving Significance of Tumor-Normal Sequencing in Cancer Care
Diana Mandelker et al.
TRENDS IN CANCER (2020)
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Everett J. Moding et al.
NATURE CANCER (2020)
Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
Kartik Sehgal et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers
Joshua K. Sabari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
B. T. Li et al.
ANNALS OF ONCOLOGY (2019)
Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib
Samantha X. Y. Wang et al.
ANTI-CANCER DRUGS (2019)
Performance evaluation of commercial library construction kits for PCR-based targeted sequencing using a unique molecular identifier
Jongsuk Chung et al.
BMC GENOMICS (2019)
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Sabrina Baltschukat et al.
CLINICAL CANCER RESEARCH (2019)
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation
Benjamin P. Brown et al.
CLINICAL CANCER RESEARCH (2019)
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer
Yasushi Yatabe et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Morana Vojnic et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions
Young Kwang Chae et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC
Zhen Wu et al.
CANCER MEDICINE (2019)
Immunocytochemistry for predictive biomarker testing in lung cancer cytology
Deepali Jain et al.
CANCER CYTOPATHOLOGY (2019)
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer
Natasha B. Leighl et al.
CLINICAL CANCER RESEARCH (2019)
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed et al.
CLINICAL CANCER RESEARCH (2019)
DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer
Kurtis D. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Neuregulin 1 Fusion-Positive NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
High efficiency error suppression for accurate detection of low-frequency variants
Ting Ting Wang et al.
NUCLEIC ACIDS RESEARCH (2019)
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
Kevin Lou et al.
SCIENCE SIGNALING (2019)
Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study
Guannan Kang et al.
BMC CANCER (2019)
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Jing Liu et al.
BMC CANCER (2019)
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Robin Guo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Drugging an undruggable pocket on KRAS
Dirk Kessler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib
Lei Ma et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
Sergio Villatoro et al.
MOLECULAR ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib
Pei N. Ding et al.
THORACIC CANCER (2019)
1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
A Marabelle et al.
ANNALS OF ONCOLOGY (2019)
536TiPINSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
J C-H Yang et al.
ANNALS OF ONCOLOGY (2019)
Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
R. Govindan et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
A. Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Pedram Razavi et al.
NATURE MEDICINE (2019)
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal et al.
SCIENCE (2019)
Molecular Testing Strategies for Pulmonary Adenocarcinoma An Optimal Approach With Cost Analysis
Lester J. Layfield et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis
Laetitia Lambros et al.
CLINICAL LUNG CANCER (2019)
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
JAMA ONCOLOGY (2019)
Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.
Solange Peters et al.
CANCER RESEARCH (2019)
How I treat ALK-positive non-small cell lung cancer
Michael G. McCusker et al.
ESMO OPEN (2019)
Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers
Vijaya G. Tirunagaru et al.
CANCER RESEARCH (2019)
Novel RAS inhibitor, MCI-062, potently and selectively inhibits the growth of KRAS mutant pancreatic tumor cells by blocking GTP loading of RAS
Tyler E. Mattox et al.
CANCER RESEARCH (2019)
Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M. Schram et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA)
Wenhua Liang et al.
THERANOSTICS (2019)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Yuebi Hu et al.
CLINICAL CANCER RESEARCH (2018)
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard et al.
CLINICAL CANCER RESEARCH (2018)
A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants
Muyang He et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
Travis A. Clark et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer
Roberto Ferrara et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinical analysis by next-generation sequencing for NSCLC patients with &ITMET&IT amplification resistant to osimertinib
Yubo Wang et al.
LUNG CANCER (2018)
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis
Huy Gia Vuong et al.
LUNG CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling
Vincent Plagnol et al.
PLOS ONE (2018)
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
Pang-Dian Fan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation
Frederick H. Wilson et al.
CANCER DISCOVERY (2018)
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
Alexander Drilon et al.
CANCER DISCOVERY (2018)
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2018)
Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression
Domenico Trombetta et al.
Oncotarget (2018)
Role of circulating tumor DNA in the management of early-stage lung cancer
Heng Zhao et al.
THORACIC CANCER (2018)
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
Ryan N. Ptashkin et al.
JAMA ONCOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.
Charles Swanton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab (Nivo) plus platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition
Lei Deng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Tobias Grabe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
S S Ramalingam et al.
ANNALS OF ONCOLOGY (2018)
TNER: a novel background error suppression method for mutation detection in circulating tumor DNA
Shibing Deng et al.
BMC BIOINFORMATICS (2018)
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing
Thomas P. Slavin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro
Masaya Nishino et al.
LUNG CANCER (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Discovery of JND3229 as a New EGFR(C797S) Mutant Inhibitor with In Vivo Monodrug Efficacy
Xiaoyun Lu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Jana Fassunke et al.
NATURE COMMUNICATIONS (2018)
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma
Etienne Giroux-Leprieur et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target
Christina I. Selinger et al.
HISTOPATHOLOGY (2017)
UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy
Tom Smith et al.
GENOME RESEARCH (2017)
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer
Reinhard Buttner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Oliver Gautschi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib
Parneet K. Cheema et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions
Nathan D. Gay et al.
Journal of Thoracic Oncology (2017)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Thanyanan Reungwetwattana et al.
LUNG CANCER (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Direct detection of early-stage cancers using circulating tumor DNA
Jillian Phallen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh et al.
LANCET RESPIRATORY MEDICINE (2017)
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer
Wei Wu et al.
CANCERS (2017)
Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
Yuebi Hu et al.
CLINICAL CANCER RESEARCH (2017)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Jaclyn F. Hechtman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
Catherine C. Coombs et al.
CELL STEM CELL (2017)
Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens
Lukas Bubendorf et al.
EUROPEAN RESPIRATORY REVIEW (2017)
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy
Sara Pilotto et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases
Hideko Isozaki et al.
CANCER RESEARCH (2016)
Liquid Biopsy in Lung Cancer A Perspective From Members of the Pulmonary Pathology Society
Lynette M. Sholl et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement
Jieyu Wu et al.
BMC CANCER (2016)
Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit
Takahiko Murayama et al.
CANCER RESEARCH (2016)
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Ferdinandos Skoulidis et al.
CLINICAL CANCER RESEARCH (2016)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Mark M. Awad et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Xuewen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer
Patrizia Viola et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
cMET Exon 14 Skipping: From the Structure to the Clinic
Nele Van der Steen et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
Bob T. Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
Karen L. Reckamp et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Alexander Drilon et al.
LANCET ONCOLOGY (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Integrated digital error suppression for improved detection of circulating tumor DNA
Aaron M. Newman et al.
NATURE BIOTECHNOLOGY (2016)
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Rebecca S. Heist et al.
ONCOLOGIST (2016)
Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101
Ramamoorthy Nagasubramanian et al.
PEDIATRIC BLOOD & CANCER (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung
Dong Hoon Shin et al.
ONCOTARGET (2016)
NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma
Michael Duruisseaux et al.
CANCER MEDICINE (2016)
Liquid Biopsy in Non-Small Cell Lung Cancer
Miguel A. Molina-Vila et al.
FRONTIERS IN MEDICINE (2016)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
Helena A. Yu et al.
JAMA ONCOLOGY (2015)
Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma
Yanyan Lou et al.
Clinical Lung Cancer (2015)
Clinical Next-Generation Sequencing in Patients with Non-Small Cell Lung Cancer
Ian S. Hagemann et al.
CANCER (2015)
Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
Seung Eun Lee et al.
MODERN PATHOLOGY (2015)
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
K. Tsuta et al.
BRITISH JOURNAL OF CANCER (2014)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2014)
Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Takashi Nakaoku et al.
CLINICAL CANCER RESEARCH (2014)
Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations
Adi Gazdar et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort
Helena A. Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma
Tatsuji Mizukami et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Crizotinib Can Overcome Acquired Resistance to CH5424802
Toyokawa Gouji et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes
Saravana M. Dhanasekaran et al.
NATURE COMMUNICATIONS (2014)
CD74-NRG1 Fusions in Lung Adenocarcinoma
Lynnette Fernandez-Cuesta et al.
CANCER DISCOVERY (2014)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2013)
RET fusion gene: Translation to personalized lung cancer therapy
Takashi Kohno et al.
CANCER SCIENCE (2013)
Circulating cell free DNA: Preanalytical considerations
Safia El Messaoudi et al.
CLINICA CHIMICA ACTA (2013)
Concurrent Molecular Alterations in Tumors With Germ Line Epidermal Growth Factor Receptor T790M Mutations
Anish Thomas et al.
CLINICAL LUNG CANCER (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan et al.
CLINICAL CANCER RESEARCH (2012)
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
Young Seok Ju et al.
GENOME RESEARCH (2012)
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer
Rui Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
KIF5B-RET fusions in lung adenocarcinoma
Takashi Kohno et al.
NATURE MEDICINE (2012)
Sequence error storms and the landscape of mutations in cancer
Stefan Kirsch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients
Carmelo Tibaldi et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Sequence-specific error profile of Illumina sequencers
Kensuke Nakamura et al.
NUCLEIC ACIDS RESEARCH (2011)
ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice
Mary Beth Beasley et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners
Zhaomin Li et al.
CELLULAR SIGNALLING (2007)
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
DW Bell et al.
NATURE GENETICS (2005)
Multiple novel transcription initiation sites for NRG1
V Steinthorsdottir et al.
GENE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Neuregulins: functions, forms, and signaling strategies
DL Falls
EXPERIMENTAL CELL RESEARCH (2003)
Share Paper
